CRACKING CANCER DAVID SUZUKI

The article highlights the conundrum posed by decades old thinking in an era of innovation. Namely, how does the FDA approve a treatment modality without their sacred clinical trials?

If we propose to do treatment based on an individual's perhaps unique genetic mutation, we can't expect to find 10's or 100's of clinical trial subjects with the same unique mutation.